Surgical Treatment for Heart Failure
Update Date：2026/04/07，
Views：16
I-Chang Lin, M.D. Attending Surgeon, Division of Cardiovascular Surgery Tri-Service General Hospital
Feature 1: Acute Intervention — The "Survival Outpost" for Cardiogenic Shock: ECMO and CentriMag (Short-term VAD) Introduction: When the Heart Hits the Pause Button
The acute exacerbation of heart failure is often accompanied by cardiogenic shock. This represents a total physiological collapse: as the heart’s pumping function drops to a freezing point, systemic blood circulation nearly grinds to a halt. Within hours, the brain, kidneys, and liver begin to fail due to oxygen deprivation.
In these "life-and-death" moments, inotropic medications are often too slow to address the crisis. At this critical juncture, the medical team must rapidly initiate Mechanical Circulatory Support (MCS). These devices act as "pinch hitters" for the heart, taking over blood circulation and securing a fighting chance for the patient’s survival.
ECMO: A Multidisciplinary Pioneer in Emergency Rescue
Extracorporeal Membrane Oxygenation (ECMO) is currently the most widely known life-support equipment. Essentially, it is an artificial system designed to temporarily replace the functions of both the heart and the lungs.
Operational Logic: The Procedure
The surgeon inserts two large-bore cannulas into the patient’s femoral vein and femoral artery. Blood is drawn from the vein and directed into a machine where it passes through an "artificial lung (oxygenator)" for gas exchange—removing carbon dioxide and infusing oxygen. Subsequently, a centrifugal pump pushes the bright red, oxygenated blood back into the arterial system.
The Tactical Value of "Buying Time"
The greatest advantage of ECMO is speed. It can be rapidly deployed in the emergency room or even inside an ambulance. However, the medical community defines it as a "Bridge to Decision." This is because ECMO increases the heart's afterload (resistance), making it an unsustainable long-term solution. It buys a window of 7 to 14 days, allowing physicians to evaluate whether the heart can recover through rest or if a transition to more advanced therapies is required.
CentriMag (Short-term VAD): More Stable, More Gentle Extracorporeal Support
When a patient requires support for more than two weeks, or when ECMO leads to complications, the CentriMag (Short-term Ventricular Assist Device) takes center stage.
Precision in Magnetic Levitation (Maglev) Technology
The CentriMag utilizes a maglev centrifugal pump. While traditional mechanical pumps may damage red blood cells due to component wear or heat generation, the magnetic levitation design minimizes hemolysis (red blood cell damage) and the risk of thrombosis (blood clots).
The Flexibility of Shunt Support
The system offers the flexibility to provide isolated support for either the left ventricle (directing blood flow to the aorta) or the right ventricle (directing blood flow to the pulmonary artery). Compared to ECMO, CentriMag exerts less pressure on the heart and provides a more stable blood flow, with support duration extending up to several months. It serves as the most critical "transfer station" for patients transitioning from acute shock to a heart transplant or a long-term heart pump, such as the HeartMate 3.
The Dilemmas and Challenges of Acute Intervention
Despite these technologies being hailed as "life-saving breakthroughs," they carry significant risks. Prolonged placement of cannulas can lead to severe infections. Furthermore, to prevent blood from clotting within the system, anticoagulants must be administered, which in turn increases the risk of intracranial hemorrhage or gastrointestinal bleeding.
Ultimately, the success of acute intervention is not defined by the moment the machine is initiated, but by the medical team’s ability to precisely identify the window for weaning or heart transplantation—acting strategically before complications arise.
I-Chang Lin, M.D. Attending Surgeon, Division of Cardiovascular Surgery Tri-Service General Hospital
Foreword: Transitioning from "Perishing" to "Coexisting"
For patients with chronic end-stage heart failure, life often feels like a slow-motion suffocation. When simple tasks like dressing or bathing leave a patient breathless, and the dosage of inotropic agents has reached the absolute limit of physical tolerance, the goal of treatment shifts from "resuscitation" to "quality of life." At this stage, the Left Ventricular Assist Device (LVAD) and optimized medical therapy emerge as the two pillars of this long-term battle.
LVAD: The Powerhouse Residing Within
The Left Ventricular Assist Device (LVAD), often referred to as an "artificial heart," stands as one of the greatest inventions in modern medicine.
Mechanism and Design
The LVAD does not replace the patient’s existing heart. Instead, it is a titanium pump, roughly the size of a hockey puck, implanted at the apex of the left ventricle. Acting like a powerful water pump, it draws blood from the ventricle, bypassing the weakened myocardium, and pumps it directly into the aorta.
Two Primary Strategic Applications
Bridge to Transplantation (BTT): Providing patients awaiting a donor heart with sufficient physical strength and organ function.
Destination Therapy (DT): For elderly patients or those ineligible for transplantation, the LVAD becomes their lifelong cardiac partner. Clinical data shows that the two-year survival rate for modern LVAD patients is now comparable to that of heart transplant recipients.
Living with the Device
The "cost" of life with an LVAD includes a driveline that exits the abdomen, connecting the internal pump to an external controller and two batteries (worn in a holster or bag). This means the patient "must never run out of power." While swimming is restricted, most patients can return to work and even enjoy activities like golf or hiking.
Heart Failure Drug Therapy: The "Fantastic Four" of Cardiac Protection
Even after the implantation of an artificial heart, medication remains the cornerstone for optimizing the body’s physiological environment. Modern medicine has established four core drug classes, known as the "Fantastic Four," which have fundamentally rewritten the prognosis for heart failure:
• ARNI (Angiotensin Receptor-Neprilysin Inhibitor): Replacing traditional medications, ARNI powerfully unloads the heart and protects the myocardium from being overstretched.
• Beta-Blockers: Acting like "blinders" for a weary horse, these drugs slow the heart rate and reduce oxygen consumption, preventing over-excitation of the sympathetic nervous system.
• SGLT2 Inhibitors: Originally for diabetes, these drugs remarkably improve myocardial metabolism and promote fluid drainage, significantly reducing hospitalization rates.
• MRA (Mineralocorticoid Receptor Antagonists): These prevent cardiac tissue from hardening (fibrosis) caused by chronic inflammation.
Conclusion: The Art of Chronic Management
The success of chronic management lies not in a single surgery, but in "precise balance." If the medication dose is too high, it leads to hypotension (low blood pressure); if it is too low, it fails to inhibit heart degradation. Meanwhile, an LVAD requires rigorous anticoagulation management and meticulous wound care. This journey demands a "Strong Triangle" formed by the medical team, the patient, and the caregivers.
Feature 3: Heart Transplantation — The Covenant of Rebirth: The Ultimate Challenges of Technique, Immunology, and Ethics
I-Chang Lin, M.D. Attending Surgeon, Division of Cardiovascular Surgery Tri-Service General Hospital
Foreword: A Medical Miracle and the Legacy of Life
Despite the rapid evolution of artificial heart technology, heart transplantation remains the "gold standard" for end-stage heart failure. It is more than just replacing a biological part; it grants the patient a living heart—one that senses emotions and accelerates naturally with exercise. This is a story of rebirth, love, and the frontiers of science.
Transplant Surgery: A Relay Race Against Time
Heart transplantation is one of the most time-sensitive and collaborative procedures in surgery.
• The Golden 4 Hours: Once a donor heart becomes available, the team must rapidly assess its function. After procurement, the heart is preserved in $4^{\circ}\text{C}$ saline. At this moment, the "cold ischemia time" begins. Ideally, the heart must resume beating within the recipient’s body within 4 to 6 hours. Every minute of delay leads to a decline in the new heart’s function.
• Surgical Precision: Surgeons remove the patient’s failing, enlarged heart, preserving portions of the atria and great vessel stumps to serve as a "cuff" or base. The donor heart is then meticulously sutured. The most profound moment for any cardiac surgeon is when the aortic cross-clamp is released, and fresh blood flows into the new heart, watching it transition from fibrillation to a rhythmic, powerful beat.
Post-operative Management: The Ultimate Duel with the Immune System
Surgical success is only the starting point; the real ordeal is the subsequent immunological battle.
• Preventing Rejection: The body identifies the new heart as a "foreign invader" and launches an attack. Consequently, recipients must take immunosuppressants for life. This is a double-edged sword: insufficient dosage leads to rejection, while excessive dosage exposes the patient to lethal infections, renal failure, and risks of lymphoma.
• Biopsy Monitoring: To detect early rejection, patients undergo regular endomyocardial biopsies. Surgeons insert a catheter through the jugular vein into the heart to retrieve tiny tissue samples to check for inflammatory cells.
The Dilemmas of Ethics and Allocation
The global demand for donor hearts far exceeds the supply. How should this precious resource be allocated? To the youngest, or to those in the most critical condition? This involves a complex scoring system. Furthermore, recipients often face "survivor’s guilt," requiring long-term psychological counseling and social support.
Conclusion: Sustaining the Flame of Life
Heart transplantation is not only a demonstration of advanced medical technology but also a profound manifestation of societal altruism and the value of life. Behind every transplant recipient lies the immense generosity of a donor family and the relentless struggle of a medical team pushing the boundaries of science.
While the future may bring breakthroughs such as xenotransplantation or the widespread use of total artificial hearts, heart transplantation remains, for now, humanity’s most sacred defense in the battle against death—a legacy of life passed from one heart to another.